+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

IgG4-Related Disease - Epidemiology Forecast to 2028

  • ID: 4827851
  • Report
  • 81 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2019
1 of 2
‘IgG4-Related Disease-Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of IgG4-Related Disease in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
IgG4-Related Disease Epidemiology
The IgG4-Related Disease epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for IgG4-Related Disease are studied through all possible division to give a better understanding of the disease scenario in the 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

IgG4-Related Disease Epidemiology Segmentation
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by:
  • Prevalent Population of IgG4-Related Disease
  • Diagnosed Prevalent Population of IgG4-Related Disease
  • Gender-specific Prevalent Population of IgG4-RD
  • Diagnosed Prevalent Population of Autoimmune Pancreatitis (AIP)
According to the author, the total diagnosed prevalent cases of IgG4-Related Disease were 204,818 in 2017 in the 7MM, which might increase by 2028.

Report Scope
  • The report covers a detailed overview of IgG4-Related Disease explaining its causes, symptoms, classification, pathophysiology, and diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of IgG4-Related Disease.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
Key Strengths
  • 10 Year Forecast of IgG4-Related Disease epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of IgG4-Related Disease
  • Prevalent Cases according to the segmentation
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Disease Background and Overview: IgG4-Related Disease
2.1. Introduction
2.2. Immunoglobulins
2.3. Clinical Manifestations
2.4. Pathophysiological Mechanisms
2.5. Symptoms
2.6. Clinical Features of Organ System Involvement
2.7. Pathophysiology
2.8. Pathogenesis of IgG4-related disease
2.9. Diagnosis

3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 7MM IgG4-Related Disease Total Patient Population
3.3. 7MM IgG4-Related Disease Total Diagnosed Patient Population

4. Country Wise-Epidemiology of IgG4-Related Disease
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. IgG4-Related Disease (IgG4-RD) Prevalent Population in the United States
4.1.3. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in the United States
4.1.4. IgG4-RD Gender-specific Prevalent Population in the United States
4.1.5. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States
4.2. EU5 Countries
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Germany
4.3.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Germany
4.3.3. IgG4-RD Gender-specific Prevalent Population in Germany
4.3.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany
4.4. France
4.4.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in France
4.4.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in France
4.4.3. IgG4-RD Gender-specific Prevalent Population in France
4.4.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France
4.5. Italy
4.5.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Italy
4.5.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Italy
4.5.3. IgG4-RD Gender-specific Prevalent Population in Italy
4.5.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy
4.6. Spain
4.6.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Spain
4.6.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Spain
4.6.3. IgG4-RD Gender-specific Prevalent Population in Spain
4.6.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain
4.7. United Kingdom
4.7.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in the United Kingdom
4.7.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in the United Kingdom
4.7.3. IgG4-RD Gender-specific Prevalent Population in the United Kingdom
4.7.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. IgG4-Related Disease (IgG4-RD) Prevalent Population in Japan
4.8.3. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Japan
4.8.4. IgG4-RD Gender-specific Prevalent Population in Japan
4.8.5. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Japan

5. Appendix
5.1. Report Methodology

6. Capabilities

7. Disclaimer

8. About the Author

List of Tables
Table 1 IgG4-Related Disease Total Population in the 7MM (2017–2028)
Table 2 IgG4-Related Disease Total Diagnosed Population in the 7MM (2017–2028)
Table 3 IgG4-RD Prevalent Population of IgG4-RD in the United States (2017–2028)
Table 4 IgG4-RD Diagnosed Prevalent Population in the United States (2017–2028)
Table 5 IgG4-RD Gender-specific Prevalent Population in the United States (2017–2028)
Table 6 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States (2017–2028)
Table 7 IgG4-RD Prevalent Population of IgG4-RD in Germany (2017–2028)
Table 8 IgG4-RD Diagnosed Prevalent Population in Germany (2017–2028)
Table 9 IgG4-RD Gender-specific Prevalent Population in Germany (2017–2028)
Table 10 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany (2017–2028)
Table 11 IgG4-RD Prevalent Population of IgG4-RD in France (2017–2028)
Table 12 IgG4-RD Diagnosed Prevalent Population in France (2017–2028)
Table 13 IgG4-RD Gender-specific Prevalent Population in France (2017–2028)
Table 14 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France (2017–2028)
Table 15 IgG4-RD Prevalent Population of IgG4-RD in Italy (2017–2028)
Table 16 IgG4-RD Diagnosed Prevalent Population in Italy (2017–2028)
Table 17 IgG4-RD Gender-specific Prevalent Population in Italy (2017–2028)
Table 18 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy (2017–2028)
Table 19 IgG4-RD Prevalent Population of IgG4-RD in Spain (2017–2028)
Table 20 IgG4-RD Diagnosed Prevalent Population in Spain (2017–2028)
Table 21 IgG4-RD Gender-specific Prevalent Population in Spain (2017–2028)
Table 22 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain (2017–2028)
Table 23 IgG4-RD Prevalent Population of IgG4-RD in the United Kingdom (2017–2028)
Table 24 IgG4-RD Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Table 25 IgG4-RD Gender-specific Prevalent Population in the United Kingdom (2017–2028)
Table 26 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Table 27 IgG4-RD Prevalent Population of IgG4-RD in Japan (2017–2028)
Table 28 IgG4-RD Diagnosed Prevalent Population in Japan (2017–2028)
Table 29 IgG4-RD Gender-specific Prevalent Population in Japan (2017–2028)
Table 30 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Japan (2017–2028)

List of Figures
Figure 1 Pathogenesis of IgG4-RD
Figure 2 Comprehensive diagnostic criteria for IgG4-RD
Figure 3 Diagnostic algorithm for IgG4-RD
Figure 4 IgG4-Related Disease Total Population in the 7MM (2017–2028)
Figure 5 IgG4-Related Disease Total Diagnosed Population in the 7MM (2017–2028)
Figure 6 IgG4-RD Prevalent Population of IgG4-RD in the United States (2017–2028)
Figure 7 IgG4-RD Diagnosed Prevalent Population in the United States (2017–2028)
Figure 8 IgG4-RD Gender-specific Prevalent Population in the United States (2017–2028)
Figure 9 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States (2017–2028)
Figure 10 IgG4-RD Prevalent Population of IgG4-RD in Germany (2017–2028)
Figure 11 IgG4-RD Diagnosed Prevalent Population in Germany (2017–2028)
Figure 12 IgG4-RD Gender-specific Prevalent Population in Germany (2017–2028)
Figure 13 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany (2017–2028)
Figure 14 IgG4-RD Prevalent Population of IgG4-RD in France (2017–2028)
Figure 15 IgG4-RD Diagnosed Prevalent Population in France (2017–2028)
Figure 16 IgG4-RD Gender-specific Prevalent Population in France (2017–2028)
Figure 17 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France (2017–2028)
Figure 18 IgG4-RD Prevalent Population of IgG4-RD in Italy (2017–2028)
Figure 19 IgG4-RD Diagnosed Prevalent Population in Italy (2017–2028)
Figure 20 IgG4-RD Gender-specific Prevalent Population in Italy (2017–2028)
Figure 21 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy (2017–2028)
Figure 22 IgG4-RD Prevalent Population of IgG4-RD in Spain (2017–2028)
Figure 23 IgG4-RD Diagnosed Prevalent Population in Spain (2017–2028)
Figure 24 IgG4-RD Gender-specific Prevalent Population in Spain (2017–2028)
Figure 25 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain (2017–2028)
Figure 26 IgG4-RD Prevalent Population of IgG4-RD in the United Kingdom (2017–2028)
Figure 27 IgG4-RD Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Figure 28 IgG4-RD Gender-specific Prevalent Population in the United Kingdom (2017–2028)
Figure 29 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Figure 30 IgG4-RD Prevalent Population of IgG4-RD in Japan (2017–2028)
Figure 31 IgG4-RD Diagnosed Prevalent Population in Japan (2017–2028)
Figure 32 IgG4-RD Gender-specific Prevalent Population in Japan (2017–2028)
Figure 33 Treatment algorithm for IgG4-RD
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll